证券代码：003017 证券简称：大洋生物 公告编号：2025-093 浙江大洋生物科技集团股份有限公司 2025 年半年度权益分派实施公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 一、股东大会审议通过的权益分派方案情况 公司于 2025 年 9 月 12 日召开的 2025 年第二次临时股东大会审议通过了《关 于 2025 年半年度利润分配预案的议案》，具体内容详见公司 2025 年 8 月 26 日 在《证券时报》《证券日报》和巨潮资讯网（http://www.cninfo.com.cn）上披露 的《关于 2025 年半年度利润分配预案的公告》（公告编号：2025-079）。 1.公司以总股本 84,000,000 股为基数，向全体股东每 10 股派发现金红利 3.00 元（含税），上述利润分配后，剩余未分配利润结转至下一年度再行分配。公司 2025 年半年度不送红股，不以资本公积金转增股本。 2.本次实施的权益分派方案披露至实施期间公司股本总额未发生变化。 3.本次实施的权益分派方案与公司 2025 年第二次临时股东大会审议通过的 权益分派方案一 ...

Core Insights - The article highlights significant year-on-year profit growth for various companies in the first three quarters, with some reporting exceptionally high increases in net profit [1] Group 1: Companies with Exceptional Profit Growth - Xinda Co., Ltd. expects a net profit increase of 2807.87%-3211.74% year-on-year [1] - Shenghe Resources anticipates a net profit growth of 696.82%-782.96% year-on-year [1] - Jiantou Energy projects a net profit rise of 231.75% year-on-year [1] - Batian Co., Ltd. forecasts a net profit increase of 230.79%-260.15% year-on-year [1] - Bai'ao Intelligent expects a net profit growth of 158.04%-210.20% year-on-year [1] Group 2: Companies with Notable Profit Increases - Tongxing Technology anticipates a net profit increase of 154.30%-233.77% year-on-year [1] - Ruixin Microelectronics projects a net profit growth of 116%-127% year-on-year [1] - Yahua Group expects a net profit increase of 106.97%-132.84% year-on-year [1] - Suihengyun A anticipates a net profit rise of 87.83%-180.38% year-on-year [1] - Taishan Petroleum projects a net profit increase of 87%-125% year-on-year [1] Group 3: Companies with Moderate Profit Growth - Shandong Gold anticipates a net profit increase of 83.9%-98.5% year-on-year [1] - Lutai A expects a net profit growth of 70.23%-84.12% year-on-year [1] - Zongshen Power projects a net profit increase of 70%-100% year-on-year [1] - Zijang Enterprises anticipates a net profit rise of 70%-90% year-on-year [1] - Jinjiang Shipping expects a net profit increase of 62.72%-66.89% year-on-year [1] Group 4: Companies with Lower but Positive Profit Growth - Jieshun Technology anticipates a net profit increase of 58.11%-86.01% year-on-year [1] - Gibit expects a net profit growth of 57%-86% year-on-year [1] - Xindong Link expects a net profit increase of 56.43%-91.19% year-on-year [1] - Tongda Co., Ltd. (rights protection) anticipates a net profit increase of 50.01%-111.12% year-on-year [1] - Dongwu Securities projects a net profit growth of 50%-65% year-on-year [1] Group 5: Companies Reporting Turnaround - Yuanda Intelligent (rights protection) expects a net profit of 33.83 million to 50.73 million, marking a turnaround [1] - Luoxin Pharmaceutical (rights protection) anticipates a net profit of 22.70 million to 25.20 million, indicating a turnaround [1] - Zhongke Sanhuan expects a net profit of 80 million to 100 million, also indicating a turnaround [1]

证券日报网讯 10月14日晚间，大洋生物发布2025年前三季度业绩预告称，公司预计2025年前三季度归 属于上市公司股东的净利润为7，400万元—9，000万元，比上年同期增长44.35%—75.56%。 （编辑 任世碧） ...

Core Viewpoint - The company expects a significant increase in net profit for the first three quarters, driven by higher demand for its main products, potassium carbonate and veterinary raw materials, resulting in increased sales and prices [1] Financial Performance - The net profit attributable to shareholders is projected to be between 74 million and 90 million yuan, representing a year-on-year growth of 44.35% to 75.56% [1] - The net profit after deducting non-recurring gains and losses is expected to be between 67 million and 82 million yuan, indicating a year-on-year increase of 39.04% to 70.17% [1] Market Influence - The increase in net profit is primarily attributed to market influences that have boosted the demand for the company's main products [1] - Both sales volume and prices have risen compared to the same period last year, contributing to an increase in gross profit margin [1]

Core Viewpoint - The company, Dayang Bio (003017.SZ), anticipates a significant increase in net profit for the first three quarters of 2025, driven by rising demand for its main products, potassium carbonate and veterinary raw materials [1] Financial Performance - The company expects net profit attributable to shareholders to be between 74 million and 90 million yuan, representing a year-on-year growth of 44.35% to 75.56% [1] - The net profit after deducting non-recurring gains and losses is projected to be between 67 million and 82 million yuan, indicating a year-on-year increase of 39.04% to 70.17% [1] Market Influence - The increase in net profit is primarily attributed to market influences that have boosted the demand for the company's main products [1] - Both sales volume and prices of potassium carbonate and veterinary raw materials have risen compared to the same period last year, contributing to the improved gross margin [1]

Core Viewpoint - The company, Dayang Bio (003017.SZ), anticipates a significant increase in net profit for the first three quarters of 2025, driven by rising demand for its main products, potassium carbonate and veterinary raw materials [1] Financial Performance - The company expects net profit attributable to shareholders to be between 74 million and 90 million yuan, representing a year-on-year growth of 44.35% to 75.56% [1] - The net profit after deducting non-recurring gains and losses is projected to be between 67 million and 82 million yuan, indicating a year-on-year increase of 39.04% to 70.17% [1] Market Factors - The increase in net profit is primarily attributed to market influences that have boosted the demand for the company's main products [1] - Both sales volume and prices of potassium carbonate and veterinary raw materials have risen compared to the same period last year, contributing to the improved gross margin [1]

Core Viewpoint - The company, Dayang Biological (003017.SZ), expects a significant increase in net profit for the first three quarters, driven by rising demand for its main products, potassium carbonate and veterinary raw materials, due to market influences [1] Financial Performance - The net profit attributable to shareholders is projected to be between 74 million and 90 million yuan, representing a year-on-year growth of 44.35% to 75.56% [1] - The net profit after deducting non-recurring gains and losses is expected to be between 67 million and 82 million yuan, indicating a growth of 39.04% to 70.17% compared to the same period last year [1] Market Dynamics - The increase in net profit is attributed to higher sales volumes and prices of the company's main products, along with an improvement in gross profit margins [1]

Core Viewpoint - The company expects a significant increase in net profit attributable to shareholders for the first three quarters, driven by market demand for its main products, potassium carbonate and veterinary raw materials [1] Financial Performance - The projected net profit for the first three quarters is between 74 million and 90 million yuan, representing a year-on-year growth of 44.35% to 75.56% [1] - The increase in performance is attributed to higher sales volumes and prices compared to the same period last year, along with an improvement in gross profit margin [1]

Core Insights - The company expects a net profit of 74 million yuan for the first three quarters of 2025, representing a growth of 44.35% to 75.56% compared to the same period last year [1] Group 1: Financial Performance - The projected net profit for the first three quarters of 2025 is 74 million yuan, an increase from 51.2658 million yuan in the same period last year [1] - The growth rate of net profit is estimated to be between 44.35% and 75.56% [1] Group 2: Product Demand and Pricing - There has been an increase in demand for the main products, potassium carbonate and veterinary raw materials [1] - Both sales volume and prices have risen during the reporting period [1] - The gross profit margin has improved [1]

[I. Expected Performance for the Current Period](index=1&type=section&id=%E4%B8%80%E3%80%81%E6%9C%AC%E6%9C%9F%E4%B8%9A%E7%BB%A9%E9%A2%84%E8%AE%A1%E6%83%85%E5%86%B5) The company forecasts a year-on-year increase in net profit attributable to shareholders and net profit after non-recurring items for Q1-Q3 2025, with net profit expected between 74 million and 90 million yuan, a growth of 44.35% to 75.56% [1. Performance Forecast Period](index=1&type=section&id=1.%E4%B8%9A%E7%BB%A9%E9%A2%84%E5%91%8A%E6%9C%9F%E9%97%B4) This section specifies the period covered by the performance forecast - The performance forecast covers the period from **January 1, 2025, to September 30, 2025**[3](index=3&type=chunk) [2. Performance Forecast Details](index=1&type=section&id=2.%E4%B8%9A%E7%BB%A9%E9%A2%84%E5%91%8A%E6%83%85%E5%86%B5) This section details the company's projected net profit and related financial metrics for the forecast period - The company expects positive net profit for Q1-Q3 2025, showing a **year-on-year increase** compared to the same period last year[4](index=4&type=chunk) Key Financial Indicators for Q1-Q3 2025 Performance Forecast (Unit: 10,000 yuan) | Item | Estimated Range for Current Period (10,000 yuan) | Same Period Last Year (10,000 yuan) | Year-on-Year Growth | | :--- | :--- | :--- | :--- | | Net Profit Attributable to Shareholders | 7,400 — 9,000 | 5,126.58 | 44.35% — 75.56% | | Net Profit After Non-Recurring Items | 6,700 — 8,200 | 4,818.72 | 39.04% — 70.17% | | Basic Earnings Per Share (yuan/share) | 0.91 — 1.11 | 0.62 | - | [II. Communication with Accounting Firm](index=2&type=section&id=%E4%BA%8C%E3%80%81%E4%B8%8E%E4%BC%9A%E8%AE%A1%E5%B8%88%E4%BA%8B%E5%8A%A1%E6%89%80%E6%B2%9F%E9%80%9A%E6%83%85%E5%86%B5) The financial data in this performance forecast has not been pre-audited by an accounting firm - The financial data in this performance forecast has not been pre-audited by **Zhonghui Certified Public Accountants (Special General Partnership)**[6](index=6&type=chunk) [III. Explanation of Performance Changes](index=2&type=section&id=%E4%B8%89%E3%80%81%E4%B8%9A%E7%BB%A9%E5%8F%98%E5%8A%A8%E5%8E%9F%E5%9B%A0%E8%AF%B4%E6%98%8E) Net profit growth is primarily due to increased market demand, driving up sales and prices of key products like potassium carbonate and veterinary APIs, thereby improving gross margin - The primary reason for the year-on-year increase in net profit is **increased market demand**, which drove up both sales volume and prices of key products like **potassium carbonate and veterinary APIs**[7](index=7&type=chunk) - The rise in sales volume and prices of main products led to an **increase in the company's gross margin**[7](index=7&type=chunk) [IV. Risk Warning](index=2&type=section&id=%E5%9B%9B%E3%80%81%E9%A3%8E%E9%99%A9%E6%8F%90%E7%A4%BA) The company advises investors that this performance forecast is a preliminary estimate, with final financial data subject to the officially disclosed Q3 2025 report, and highlights investment risks - This performance forecast represents the **preliminary estimation** by the company's finance department[8](index=8&type=chunk) - The definitive financial data will be based on the company's officially disclosed **Q3 2025 report**[8](index=8&type=chunk) - The company advises investors to **exercise caution** in their decisions and be aware of **investment risks**[8](index=8&type=chunk)